Sarah Larney1, Amy Peacock2, Bradley M Mathers3, Matthew Hickman4, Louisa Degenhardt5. 1. National Drug and Alcohol Research Centre, UNSW Australia, Sydney, Australia; Alpert Medical School, Brown University, Providence, RI, USA. Electronic address: s.larney@unsw.edu.au. 2. National Drug and Alcohol Research Centre, UNSW Australia, Sydney, Australia; School of Medicine, University of Tasmania, Hobart, TAS, Australia. 3. The Kirby Institute, UNSW Australia, Sydney, Australia. 4. School of Social and Community Medicine, University of Bristol, UK. 5. National Drug and Alcohol Research Centre, UNSW Australia, Sydney, Australia; School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia; Murdoch Children's Research Institute, Melbourne, VIC, Australia; Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Non-viral injecting-related injuries and diseases (IRID), such as abscesses and vascular damage, can result in significant morbidity and mortality if untreated. There has been no systematic assessment of the prevalence of non-viral IRID among people who inject drugs; this review aimed to address this gap, as well as identify risk factors for experience of specific IRID. METHODS: We searched MEDLINE, Embase and CINAHL databases to identify studies on the prevalence of, or risk factors for, IRID directly linked to injecting in samples of people who inject illicit drugs. RESULTS: We included 33 studies: 29 reported IRID prevalence in people who inject drugs, and 17 provided data on IRID risk factors. Skin and soft tissue infections at injecting sites were the most commonly reported IRID, with wide variation in lifetime prevalence (6-69%). Female sex, more frequent injecting, and intramuscular and subcutaneous injecting appear to be associated with skin and soft tissue infections at injecting sites. Cleaning injecting sites was protective against skin infections. Other IRID included infective endocarditis (lifetime prevalence ranging from 0.5-12%); sepsis (2-10%); bone and joint infections (0.5-2%); and thrombosis and emboli (3-27%). CONCLUSIONS: There were significant gaps in the data, including a dearth of research on prevalence of IRID in low- and middle-income countries, and potential risk and protective factors for IRID. A consistent approach to measurement, including standardised definitions of IRID, is required for future research.
BACKGROUND: Non-viral injecting-related injuries and diseases (IRID), such as abscesses and vascular damage, can result in significant morbidity and mortality if untreated. There has been no systematic assessment of the prevalence of non-viral IRID among people who inject drugs; this review aimed to address this gap, as well as identify risk factors for experience of specific IRID. METHODS: We searched MEDLINE, Embase and CINAHL databases to identify studies on the prevalence of, or risk factors for, IRID directly linked to injecting in samples of people who inject illicit drugs. RESULTS: We included 33 studies: 29 reported IRID prevalence in people who inject drugs, and 17 provided data on IRID risk factors. Skin and soft tissue infections at injecting sites were the most commonly reported IRID, with wide variation in lifetime prevalence (6-69%). Female sex, more frequent injecting, and intramuscular and subcutaneous injecting appear to be associated with skin and soft tissue infections at injecting sites. Cleaning injecting sites was protective against skin infections. Other IRID included infective endocarditis (lifetime prevalence ranging from 0.5-12%); sepsis (2-10%); bone and joint infections (0.5-2%); and thrombosis and emboli (3-27%). CONCLUSIONS: There were significant gaps in the data, including a dearth of research on prevalence of IRID in low- and middle-income countries, and potential risk and protective factors for IRID. A consistent approach to measurement, including standardised definitions of IRID, is required for future research.
Authors: John Strang; Nora D Volkow; Louisa Degenhardt; Matthew Hickman; Kimberly Johnson; George F Koob; Brandon D L Marshall; Mark Tyndall; Sharon L Walsh Journal: Nat Rev Dis Primers Date: 2020-01-09 Impact factor: 52.329
Authors: David Hyung Won Oh; Alysse Gail Wurcel; David Joseph Tybor; Deirdre Burke; Mariano E Menendez; Matthew Joseph Salzler Journal: Clin Orthop Relat Res Date: 2018-08 Impact factor: 4.176
Authors: Alysse G Wurcel; Deirdre Burke; Margie Skeer; David Landy; Robert Heimer; John B Wong; Kenneth K H Chui; Thomas J Stopka Journal: Drug Alcohol Depend Date: 2018-02-20 Impact factor: 4.492
Authors: Natalie L McCarthy; James Baggs; Isaac See; Sujan C Reddy; John A Jernigan; Runa H Gokhale; Anthony E Fiore Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 9.079
Authors: Louisa Degenhardt; Jason Grebely; Jack Stone; Matthew Hickman; Peter Vickerman; Brandon D L Marshall; Julie Bruneau; Frederick L Altice; Graeme Henderson; Afarin Rahimi-Movaghar; Sarah Larney Journal: Lancet Date: 2019-10-23 Impact factor: 79.321
Authors: Ricky N Bluthenthal; Daniel Chu; Lynn D Wenger; Philippe Bourgois; Thomas Valente; Alex H Kral Journal: Drug Alcohol Depend Date: 2018-02-15 Impact factor: 4.492